Toulouse University Hospital

Lixisenatide Shows Promise in Slowing Parkinson's Disease Progression in Phase 2 Trial

4 months ago

• A Phase 2 trial of Sanofi's lixisenatide demonstrated the GLP-1 agonist's potential to halt motor symptom progression in Parkinson's disease patients over 12 months. • The LixiPark study revealed patients receiving lixisenatide maintained stable motor function scores, while the placebo group experienced a 3.04-point decline in MDS-UPDRS III scores. • The findings, published in the New England Journal of Medicine, suggest a possible breakthrough in neuroprotective treatment for Parkinson's, though longer studies are needed to confirm clinical significance.